Examination of CD44/PAK1/AKT activation could help to predict response to FGFR1 inhibition, and combination with AKT or PAK1 inhibitors might pave the way toward an effective therapy for FGFR1-dependent lung-cancer patients in cases of resistance to treatment. The gene discussed is PAK1; the disease is lung cancer.